As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors ...

Ligand Pharmaceuticals (LGND) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Ligand Pharmaceuticals announced that its partner, Pelthos Therapeutics, has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum, ...

The Relative Strength (RS) Rating for Ligand PharmaceuticalsLGND stock entered a new percentile Thursday, with an increase from 80 to 84. Please watch the video at Investors.com - What Is An Extended ...

Ligand Pharmaceuticals' diversified royalty platform offers strong biotech exposure with reduced risk, supported by robust royalty revenue growth and a solid cash position. Despite a 28% royalty ...

Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable ...